AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA ...Middle East

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone...

Read More Details
Finally We wish PressBee provided you with enough information of ( AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA )

Also on site :

• Northern Ireland riots latest: Petrol bombs and fireworks hurled at police as Ballymena violence spreads
• NBA Star Shares ‘Fond Memories’ of Brian Wilson and Fans Can’t Believe They’re Related
• Protests spread across US despite Trump threats